Drug Profile

ASKG 843

Alternative Names: ASKG-843

Latest Information Update: 28 May 2025

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator AskGene Pharma
Class Antineoplastics; Immunotherapies; Recombinant fusion proteins
Mechanism of Action Programmed cell death-1 ligand-1 inhibitors; TGF-beta superfamily protein inhibitors

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

Highest Development Phases

No development reported Cancer

Most Recent Events

28 May 2025 No recent reports of development identified for preclinical development in Cancer in USA
10 Apr 2021 Pharmacodynamics and safety data from a preclinical study in Cancer presented at the 112^th Annual Meeting of the American Association for Cancer Research (AACR-2021)
01 Apr 2021 Preclinical trials in Cancer in USA (unspecified route)

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com